Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Champions Oncology (CSBR) Accumulated Depreciation & Amortization (2016 - 2026)

Champions Oncology has reported Accumulated Depreciation & Amortization over the past 15 years, most recently at $1.1 million for Q1 2026.

  • For Q1 2026, Accumulated Depreciation & Amortization fell 15.25% year-over-year to $1.1 million; the TTM value through Jan 2026 reached $1.1 million, down 15.25%, while the annual FY2025 figure was $1.6 million, 13.68% down from the prior year.
  • Accumulated Depreciation & Amortization for Q1 2026 was $1.1 million at Champions Oncology, up from $715000.0 in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $2.2 million in Q2 2023 and troughed at $358000.0 in Q3 2025.
  • A 5-year average of $1.0 million and a median of $848000.0 in 2024 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 329.29% in 2023 and later plummeted 71.71% in 2024.
  • Year by year, Accumulated Depreciation & Amortization stood at $1.1 million in 2022, then tumbled by 55.51% to $484000.0 in 2023, then soared by 75.21% to $848000.0 in 2024, then decreased by 15.68% to $715000.0 in 2025, then soared by 47.69% to $1.1 million in 2026.
  • Business Quant data shows Accumulated Depreciation & Amortization for CSBR at $1.1 million in Q1 2026, $715000.0 in Q4 2025, and $358000.0 in Q3 2025.